Loading
Viromed Medical AG Stock: price and insider trades · Germany
1 insider bought €11k of shares over the last 90 days, the latest filed 08 Sept 2026.
Viromed Medical AG: what insiders have been doing
Every trade that managers of Viromed Medical AG disclose to BaFin is tracked on this page. The company sits in the Healthcare & Pharma sector. 4 insiders have disclosed 31 filings since 18 October 2025.
Purchases and sales both appear in the filings: 11 purchases (3 insiders, €219k) and 20 sales (3 insiders, €6.2M). Taken together, the sales exceed the purchases by €6.0M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 2 senior executives. Perbandt, Uwe filed the largest sale, €2.3M, on 14 January 2026.
In all, 2 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (8 September 2026) now reads 39 days. Typically, a trade is published a median of 5 days after it takes place. Under the Market Abuse Regulation, managers have three business days to notify their trades. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (287 companies, median 5 filings), a count of 31 filings is above the norm. Over the whole record (from 2025), the tally stands at 12 purchases and 25 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by BaFin and describes the past, not future prices; it is not investment advice.
Insider Decl.
37
Thresholds
n/a
Buy Volume
€240,849
12 ops. · all time
Sell Volume
€7M
25 ops. · all time
Who traded when
BuySaleUwe Perbandt10 buys16 sales
Heike Perbandt10 sales
Perbamed Invest GmbH2 buys
Fundamental score
Ranked 14,000 of 24,148 companies
46.9
score / 100
Value33
Quality60
FCF yld·
Earn yld0.6%
EV/EBITDA·
ROE4.3%
Gross mgn45%
Net mgn12%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€4.82
Analyst consensus
1 analysts2.00/5
€11.00Target €11.00(+128%)€11.00
Income statement
Revenue€5.1M
Gross profit€2.3M45% margin
EBITDA-€9,707-0% margin
Net income€605k6.6% margin
Valuation
PER (trailing)190.0x
PER (forward)11.2x
P/Book9.8x
Beta1.67
Balance sheet & cash
Market cap€102.4M
Total debt€8,655
Debt / Equity1%
Profitability & ownership
ROE4.3%
ROA-7.6%
% insiders0.0%
% institutions0.1%
Last declaration on 10 October 2026
Declarations37 total
5,000 shares@ €5.780.024% mcap4.0% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-f11bab701253
8,000 shares@ €5.700.038% mcap6.4% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-472b6681f323
5,000 shares@ €5.400.025% mcap4.2% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-8a77ca677eef
10,000 shares@ €6.100.054% mcap9.9% of flowShareISIN DE000A40ZVN7BAFIN:40034243-9df6df569d22
50,000 shares@ €6.250.28% mcap50.9% of flowShareISIN DE000A40ZVN7BAFIN:40034243-8486b7fa61b9
2,000 shares@ €5.650.010% mcap0.2% of flowShareXETRAISIN DE000A40ZVN7BAFIN:40034243-45fcb05d9326
Canonical exit: 3 Dec 2026 (T+90)
8,000 shares@ €6.500.046% mcap8.5% of flowShareXETRAISIN DE000A40ZVN7BAFIN:40034243-891990855761
80,000 shares@ €6.950.49% mcap8.1% of flowShareISIN DE000A40ZVN7BAFIN:40034243-d0435f14eddd
7,500 shares@ €7.050.047% mcap8.6% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-1762c05ab8dc
10,000 shares@ €7.100.063% mcap11.6% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-57ba8d2b2bc9
50,000 shares@ €7.700.34% mcap5.6% of flowShareISIN DE000A40ZVN7BAFIN:40034243-e558057d5503
5,000 shares@ €7.600.034% mcap6.2% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-706698b18e1c
3,103.148 shares@ €7.180.014% mcap85.9% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-d9a61a9c7fd0
Canonical exit: 20 Sept 2026 (T+90)
500 shares@ €7.340.0023% mcap14.1% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-a56462f257f5
Canonical exit: 21 Sept 2026 (T+90)
500 shares@ €7.120.0025% mcap0.1% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-f043836d0405
Canonical exit: 7 Sept 2026 (T+90)
525 shares@ €7.450.0028% mcap0.1% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-4052e3215f5a
Canonical exit: 1 Sept 2026 (T+90)
2,000 shares@ €6.600.0086% mcap0.2% of flowShareXETRAISIN DE000A40ZVN7BAFIN:40034243-c4edf79fbda8
Canonical exit: 25 Aug 2026 (T+90)
9,677.126 shares@ €6.680.042% mcap0.9% of flowShareXETRAISIN DE000A40ZVN7BAFIN:40034243-feeafff117fe
Canonical exit: 11 Aug 2026 (T+90)
2,000 shares@ €7.050.0092% mcap0.2% of flowShareXETRAISIN DE000A40ZVN7BAFIN:40034243-48e6126adbe5
Canonical exit: 9 Aug 2026 (T+90)
500 shares@ €6.430.0021% mcap0.0% of flowShareXETRAISIN DE000A40ZVN7BAFIN:40034243-248e77335e4b
Canonical exit: 22 Jul 2026 (T+90)
5,000 shares@ €5.250.017% mcap4.3% of flowShareISIN DE000A40ZVN7BAFIN:40034243-3a4bced611d0
143,000 shares@ €6.300.59% mcap13.1% of flowShareISIN DE000A40ZVN7BAFIN:40034243-83acf6b4fe6e
39,108 shares@ €6.053.4% of flowShareXetraISIN DE000A40ZVN7BAFIN:40034243-8d459a65d82c
667,000 shares@ €3.5034.0% of flowShareISIN DE000A3MQR65BAFIN:40034243-85949ac82ff4
290,000 shares@ €3.5014.8% of flowShareISIN DE000A3MQR65BAFIN:40034243-f48d920430e0
25 of 37 declarations
About Viromed Medical AG
Viromed Medical AG is a German medical technology company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany. The group focuses on the development, manufacturing, and commercialization of cold atmospheric plasma (CAP) solutions, positioning itself in high-value clinical applications such as disinfection, wound healing, and selected intensive-care and pulmonology use cases. According to the company, it has been conducting basic research into viruses and bacteria since 2004 and highlighted pioneering disinfection work as early as the SARS period in 2013. The investment case is therefore built around an innovation-led medtech platform rather than a mature, broad-based device franchise. citeturn3view1turn3view3turn3view06
From a corporate structure standpoint, Viromed Medical AG is a listed holding company whose operating business is carried by its wholly owned subsidiary Viromed Medical GmbH. The company’s registered office is in Rellingen, Germany, while its stock-market communications also reference Pinneberg as a key operational location. Viromed emphasizes a broad commercial network in Germany and the wider DACH region, including hospitals, pharmacies, medical practices, elderly-care facilities, and institutional customers, alongside distribution partnerships abroad. This gives the group a relatively wide outreach for a small-cap medtech name, although commercial penetration remains tied to the adoption of its CAP platform. citeturn3view0turn3view3turn2search76
Read moreShow less
The product portfolio centers on CAP-based medical devices and applications, especially ViroCAP® and PulmoPlas®. These solutions are designed to address infection-related and wound-care use cases, with Viromed presenting CAP as a potentially disruptive approach to conventional treatment methods. In 2025, the company broadened its scope through the acquisition of pharmedix GmbH, which is active in health products, nutritional supplements, and medical cosmetics. That transaction adds a consumer-health and adjacent wellness layer to the story, while the core equity thesis still depends primarily on the medical-device and therapeutic plasma platform. citeturn3view2turn3view46
In competitive terms, Viromed remains a niche player in an emerging market. Its competitive positioning is driven less by scale than by clinical validation, regulatory progress, and the ability to convert preclinical and early clinical data into revenue. That makes execution risk material, but it also creates optionality if the technology gains broader hospital adoption. A major milestone came in 2025 with ISO 13485 certification, which is important for medical-device manufacturing and market access, and the company also advanced the approval pathway for PulmoPlas® with the relevant German authorities. citeturn3view26
Recent corporate and market developments have been meaningful. Viromed successfully started trading on Xetra in September 2024, improving liquidity and expanding its investor base. In 2025, it announced encouraging preclinical findings in respiratory indications, new distribution partnerships for Asia, veterinary medicine, and European cosmetics, and a stronger commercial outlook than in 2024. For international investors, Viromed is best viewed as a German small-cap medtech story with a high innovation quotient, meaningful regulatory milestones, and a growth narrative still dependent on clinical proof, commercialization, and execution. citeturn3view3turn3view2turn3view46
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations